Company Overview and News

to your dashboard

Headline News

10 Stocks to Buy Instead of Bitcoin

5h investorplace
There certainly has been a lot of talk about cryptocurrencies, especially bitcoin, in the past few weeks. It’s not surprising. Every investor loves the zero-to-hero story, although most never realize that dream. (65-1)

LGND / Ligand Pharmaceuticals Incorporated - Stock Institutional Ownership and Shareholders -

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has 287 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24,676,912 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, William Blair Investment Management, Llc, Bank Of America Corp /de/, State Street Corp, Knott David M, Henderson Group Plc, Victory Capital Management Inc, Cardinal Capital Management Llc /ct, and FMR LLC / Fidelity. (166-0)

5 Big Biotech Stocks To Buy In 2018

2018-01-17 investorplace
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal. These are the ones that live or die by the FDA and clinical trials. (133-0)

Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform

2018-01-12 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report)  announced that it has inked a worldwide license agreement with global innovative pharmaceutical company, Glenmark Pharmaceuticals. Per the agreement, Glenmark will be able to use the full OmniAb platform for producing mono- and bispecific human therapeutic antibodies. (15-0)

Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

2018-01-04 zacks
Although it was a slow week, a few companies announced collaboration agreements. Meanwhile, Ligand Pharmaceuticals (LGND - Free Report) raised its guidance for 2017 and GW Pharmaceuticals (GWPH - Free Report) got priority review in the United States for Epidiolex. Recap of the Week’s Most Important Stories GW’s Epidiolex Submitted for EU Approval: GW Pharmaceuticals, which has been in the news for its lead cannabinoid pipeline candidate, Epidiolex (cannabidiol or CBD), said that it has submitted a regulatory application to the European Medicines Agency (“EMA”) for Epidiolex as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (“LGS”) and Dravet syndrome. (425-0)

BRIEF-Ligand Pharmaceuticals - Expects Reduction Of Corporate Tax Rate To Reduce Deferred Tax Asset On Balance Sheet By About $40 Mln

2017-12-26 reuters

Biotech Stock Risks & Returns: An Understanding Today

2017-12-20 seekingalpha
Comparing the likely coming price ranges of a couple dozen industry-leader stocks as forecast by Market-Makers, LGND and AMGN have capital gains appeal. (82-2)

A Look at Spectrum Pharmaceuticals’ Recent Acquisitions

2017-12-12 marketrealist
Spectrum Pharmaceuticals (SPPI) acquired Talon Therapeutics in July 2013 for $11.3 million in cash and an issuance of 3.0 million shares. With this acquisition, the company obtained the worldwide rights to Marqibo. (26-2)

Medicines Company to Sell Infectious Disease Unit to Melinta

2017-11-30 zacks
The Medicines Company (MDCO - Free Report) announced that it has entered into a definitive agreement with antibiotics company, Melinta Therapeutics, Inc. (MLNT - Free Report) , for selling its infectious disease business unit for an upfront payment of $270 million. The agreement will grant Melinta worldwide rights of Orbactiv, Minocin and recently launched Vabomere. (81-1)

Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?

2017-11-30 zacks
We expect GW Pharmaceuticals plc (GWPH - Free Report) to beat expectations when it reports fiscal fourth-quarter 2017 results on Dec 4, before market opens. (44-0)

Viking Therapeutics: Buy The Rumor, Buy The News

2017-11-30 seekingalpha
Initial data was highly successful with all dosage levels achieving statistical significance in primary endpoint of showing an increase in lean body mass. No drug-related serious adverse events (SAEs) reported. (22-1)

Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

2017-11-29 zacks
Biogen (BIIB - Free Report) and Alkermes plc (ALKS - Free Report) announced a global license and collaboration agreement to develop and commercialize Alkermes’ phase III multiple sclerosis ("MS") candidate, ALKS 8700. Per the deal, Biogen was granted worldwide commercialization rights to Alkermes’ ALKS 8700 for an upfront payment of $28 million. In return, Biogen will pay Alkermes royalties at amid-teens percentage rate on global sales of ALKS 8700. (67-0)

Merck Announces $10 Billion Buyback, Hikes Dividend by 2.1%

2017-11-29 zacks
In an effort to enhance its shareholders' value, Merck (MRK - Free Report) declared a 2.1% hike in quarterly dividend to 48 cents from 47 cents per share paid last quarter. (60-0)

Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA

2017-11-29 zacks
GlaxoSmithKline plc (GSK - Free Report) in partnership with Medicines for Malaria Venture (MMV) filed a new drug application (NDA) with the FDA looking for approval of a single-dose tafenoquine to treat relapsing malaria. (39-0)

AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

2017-11-29 zacks
AstraZeneca Plc. (AZN - Free Report) announced that the European Medicines Agency (EMA) has accepted a variation to the Marketing Authorisation Application (MAAv) for the label expansion of Tagrisso (osimertinib). AstraZeneca is looking to get Tagrisso approved for the first-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations. (74-0)

CUSIP: 53220K181